Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

92.80USD
24 Jun 2019
Change (% chg)

$0.31 (+0.34%)
Prev Close
$92.49
Open
$92.43
Day's High
$92.99
Day's Low
$92.23
Volume
180,462
Avg. Vol
381,543
52-wk High
$96.31
52-wk Low
$72.31

Latest Key Developments (Source: Significant Developments)

Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz
Wednesday, 19 Jun 2019 06:00am EDT 

June 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ.AMPHASTAR PHARMACEUTICALS - MOMENTA/SANDOZ WILL PAY CO $59.9 MILLION NO LATER THAN JULY 2.AMPHASTAR PHARMACEUTICALS INC - CO, MOMENTA/SANDOZ WILL SUBMIT STIPULATIONS OF DISMISSAL OF ALL PENDING LITIGATION BETWEEN PARTIES..  Full Article

Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer
Tuesday, 28 May 2019 05:00pm EDT 

May 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS.ATARA BIOTHERAPEUTICS INC - TOUCHON WAS MOST RECENTLY AT NOVARTIS ONCOLOGY AS GLOBAL HEAD, CELL & GENE AND MEMBER OF ONCOLOGY EXECUTIVE COMMITTEE.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER STEPPED DOWN FROM HIS ROLE AS PRESIDENT, CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - DIETMAR BERGER, ATARA'S GLOBAL HEAD OF RESEARCH AND DEVELOPMENT, HAS RESIGNED.  Full Article

FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease
Friday, 24 May 2019 01:43pm EDT 

May 24 (Reuters) - Incyte Corp ::FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - JAKAFI WILL BE MADE AVAILABLE TO APPROPRIATE PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD IMMEDIATELY..INCYTE CORP - FDA APPROVED JAKAFI (RUXOLITINIB) FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER.  Full Article

Regenxbio Announces First FDA Approval Of A Gene Therapy Based On Its Proprietary Nav Technology Platform
Friday, 24 May 2019 01:14pm EDT 

May 24 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES FIRST FDA APPROVAL OF A GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM.REGENXBIO INC - ADDITIONAL APPROVALS FOR GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM ANTICIPATED IN EUROPE AND JAPAN IN 2019.  Full Article

Avexis Receives FDA Approval For Zolgensma, First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy
Friday, 24 May 2019 12:31pm EDT 

May 24 (Reuters) - Novartis AG ::AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA®, THE FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA).AVEXIS - ZOLGENSMA WILL BE MADE AVAILABLE IN THE U.S. AND WILL BE MARKETED BY AVEXIS, A NOVARTIS COMPANY.AVEXIS - ZOLGENSMA HAS PRIME (PRIORITY MEDICINES) DESIGNATION IN EUROPE, AND IS BEING REVIEWED UNDER ACCELERATED ASSESSMENT PROCEDURE.  Full Article

Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA
Thursday, 23 May 2019 07:48pm EDT 

May 24 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY.MAA FILING HAS TRIGGERED A $2.5 MILLION PAYMENT TO SOSEI HEPTARES FROM NOVARTIS.  Full Article

Cadent Therapeutics Receives Milestone Payment From Novartis
Thursday, 23 May 2019 07:00am EDT 

May 23 (Reuters) - Cadent Therapeutics: :CADENT THERAPEUTICS RECEIVES MILESTONE PAYMENT FOR INITIATION OF PHASE 2 TRIAL OF MIJ821 IN TREATMENT-RESISTANT DEPRESSION.CADENT THERAPEUTICS - ANNOUNCED RECEIPT OF SECOND MILESTONE PAYMENT FROM NOVARTIS FOLLOWING INITIATION OF A PHASE 2 CLINICAL STUDY OF MIJ821.  Full Article

Cala Health Raises $50 Mln Series C Funding
Tuesday, 21 May 2019 06:00am EDT 

May 21 (Reuters) - Novartis AG ::CALA HEALTH RAISES $50 MILLION SERIES C FUNDING.CALA HEALTH - NEW INVESTORS IN SERIES C FINANCING INCLUDE NOVARTIS, BAIRD CAPITAL, LIFESCI VENTURE PARTNERS, TRIVENTURES, AND OTHERS.CALA HEALTH INC - AS PART OF FINANCING STACY ENXING SENG WILL BE JOINING CALA HEALTH'S TEAM AS AN INDEPENDENT DIRECTOR AND BOARD CHAIR.  Full Article

Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis
Wednesday, 15 May 2019 09:01am EDT 

May 15 (Reuters) - Codexis Inc ::CODEXIS INC - ANNOUNCES SIGNING OF A CODEEVOLVER PLATFORM AGREEMENT WITH NOVARTIS.CODEXIS - UNDER TERMS, NOVARTIS WILL PAY CO UPFRONT PAYMENT, MILESTONE PAYMENTS UPON SATISFACTORY COMPLETION OF TECHNOLOGY TRANSFER.CODEXIS - WILL BE ELIGIBLE TO GET PAYMENTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS MADE WITH ENZYMES DEVELOPED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.CODEXIS INC - RECEIVES CERTAIN RIGHTS FOR FUTURE PURCHASES OF ENZYMES DEVELOPED & SOURCED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.  Full Article

Takeda says To Sell Xiidra To Novartis For Up To $5.3 Bln
Wednesday, 8 May 2019 06:30pm EDT 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES.TAKEDA PHARMACEUTICAL CO LTD - AGREES TO SELL XIIDRA TO NOVARTIS FOR UP TO $5.3 BILLION.TAKEDA PHARMACEUTICAL CO LTD - COMPANY TO ALSO DIVEST TACHOSIL TO ETHICON FOR APPROXIMATELY $400 MILLION.TAKEDA PHARMACEUTICAL CO LTD - DOES NOT EXPECT THESE DIVESTITURES TO HAVE A MATERIAL IMPACT ON ITS FY2019 CONSOLIDATED EARNINGS FORECAST.TAKEDA PHARMACEUTICAL CO LTD - INTENDS TO USE PROCEEDS FROM DIVESTITURES TO REDUCE ITS DEBT.TAKEDA PHARMACEUTICAL - FY2019 FORECAST WILL BE UPDATED AT LATER DATE TO REFLECT DIVESTITURES ONCE RELIABLE ESTIMATE OF IMPACT CAN BE MADE.TAKEDA PHARMACEUTICAL CO LTD - RECORDED FULL YEAR ADJUSTED NET SALES FOR TACHOSIL OF APPROXIMATELY $155 MILLION IN FISCAL YEAR ENDED MARCH 31, 2018..TAKEDA - ENTERED LONG-TERM MANUFACTURING SERVICES AGREEMENT, UNDER WHICH CO TO CONTINUE TO MANUFACTURE TACHOSIL PRODUCTS AND SUPPLY THEM TO ETHICON.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA WILL MAINTAIN OWNERSHIP OF MANUFACTURING FACILITY IN LINZ, AUSTRIA.  Full Article

Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.